posted a fourth-quarter net profit of $99 million, or 45 cents a share, missing the average analyst estimate of 46 cents by one penny, according to Thomson Financial/First Call. In the year-ago quarter, the company earned $79 million, or 36 cents a share.
Revenue for the quarter rose to $293 million from $238.2 million last year, driven by a 21% increase in product sales.
For the first quarter, the company expects to earn 25 cents to 29 cents a share on revenue of $315 million to $325 million. Wall Street is expecting 34 cents a share, according to First Call.
Shares of MedImmune closed at $44.92 Thursday on the